Alkermes plc
Alkermes plc, a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.
Current Price
$37.48
-2.29%GoodMoat Value
$101.41
170.6% undervaluedAlkermes plc (ALKS) Social Sentiment
ALKS Social Sentiment Analysis
Social media sentiment analysis for Alkermes plc (ALKS). Track bullish and bearish sentiment, mention volume, and BuzzScore trends from StockTwits and Reddit. Social sentiment provides a crowd-sourced view of investor confidence in ALKS.
Current stock price: $37.48. Market cap: $6.25B. This page displays sentiment timelines, bullish vs bearish ratios, total mention counts, peak BuzzScore data, and source breakdowns for ALKS. The sentiment data is updated regularly to reflect the latest social media activity.
Social sentiment is one of many signals to consider when evaluating a stock. High bullish sentiment combined with strong fundamentals may reinforce a buy thesis. Use GoodMoat's sentiment tracking alongside quality analysis, financial data, and valuation models to make well-informed investment decisions about Alkermes plc.